Oral Nifedipine Versus Placebo for Pain and Healing After Hemorrhoidectomy (NIFEDIPINE-HD)
The Effect of Oral Nifedipine Versus Placebo on Postoperative Pain and Healing Following Hemorrhoidectomy in Adult Patients: A Randomized Controlled Trial in Sana'a, Yemen
The goal of this clinical trial is to evaluate whether oral nifedipine reduces postoperative pain and improves wound healing after hemorrhoidectomy in adult patients aged 18-65 years undergoing elective surgery for grade III or IV hemorrhoids in Sana'a, Yemen.
The main questions it aims to answer are:
- Does oral nifedipine 20 mg twice daily for 14 days reduce postoperative pain compared with placebo?
- Does oral nifedipine improve wound healing progression and shorten time to complete healing compared with placebo?
Researchers will compare the nifedipine group to the placebo group to see if there is a significant reduction in pain scores, faster wound healing, lower analgesic consumption, and fewer complications.
Participants will:
- Take either oral nifedipine 20 mg or an identical-looking placebo capsule twice daily for 14 consecutive days, starting 6 hours after surgery.
- Report pain intensity using a standard 0-10 Visual Analogue Scale at multiple time points during the first 28 days.
- Attend follow-up visits on postoperative days 7, 14, and 28 for wound healing assessment and safety monitoring.
- Use rescue analgesia (paracetamol and/or diclofenac) as needed for breakthrough pain.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 4
連絡先と場所
研究連絡先
研究連絡先
- 名前:Dr. Kholood Ahmed AL-Subari, M.B.B.Ch
- 電話番号:+967772729669
- メール:drkholooda@gmail.com
研究場所
-
-
-
Sanaa、イエメン
- Al-Jumhouri Teaching Hospital
-
コンタクト:
- Dr. Kholood Ahmed AL-Subari, M.B.B.Ch
- 電話番号:+967772729669
- メール:drkholooda@gmail.com
-
主任研究者:
- Dr. Kholood Ahmed AL-Subari, M.B.B.Ch
-
コンタクト:
- Dr. Yasser Abdurabo Obadiel, Associate Professor
- メール:Yasser.Obadiel@su.edu.ye
-
-
参加基準
適格基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Adult patients aged 18-65 years
- Scheduled for elective hemorrhoidectomy for grade III or IV hemorrhoids
- Ability to provide written informed consent
- Ability to understand and complete study questionnaires
- Willingness to comply with the study protocol and follow-up visits
Exclusion Criteria:
- Known hypersensitivity to nifedipine
- Severe cardiovascular disease (unstable angina, recent myocardial infarction, severe heart failure)
- Hypotension (systolic blood pressure < 90 mmHg)
- Severe hepatic or renal impairment
- Pregnancy or breastfeeding
- Current use of calcium channel blockers or nitrates
- Emergency hemorrhoidectomy
- Concurrent inflammatory bowel disease
- History of anorectal surgery within the past 6 months
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Nifedipine 20 mg oral capsules
Oral nifedipine 20 mg capsule twice daily (every 12 hours) for 14 consecutive days.
First dose administered 6 hours after surgery.
|
Nifedipine 20 mg immediate-release oral capsule, twice daily for 14 days.
First dose 6 hours after surgery.
L-type calcium channel blocker causing internal anal sphincter smooth-muscle relaxation, reduced resting pressure, improved local blood flow, and potential anti-inflammatory/analgesic effects.
|
|
プラセボコンパレーター:Placebo oral capsules
Identical-appearing placebo capsule (same color, size, taste, and packaging) twice daily for 14 days, starting 6 hours after surgery.
|
Inert placebo capsule matched to nifedipine in color, size, taste, and packaging.
Administered twice daily for 14 days, starting 6 hours after surgery.
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Visual Analogue Scale (VAS) Pain Score
時間枠:Day 1, Day 2, Day 3, Day 7, Day 14, Day 28
|
Pain intensity measured on a 0-10 Visual Analogue Scale.
Higher scores indicate worse pain.
Assessed at rest and with defecation.
|
Day 1, Day 2, Day 3, Day 7, Day 14, Day 28
|
|
Time to Complete Wound Healing
時間枠:Up to Day 28 (censored if not healed by Day 28)
|
Number of days from surgery until complete epithelialization of all surgical wounds confirmed by clinical examination.
|
Up to Day 28 (censored if not healed by Day 28)
|
|
Redness, Edema, Ecchymosis, Discharge, Approximation (REEDA) Score
時間枠:Day 7, Day 14, Day 28
|
Redness, Edema, Ecchymosis, Discharge, Approximation (REEDA) score.
Range 0-15; lower scores indicate better healing.
|
Day 7, Day 14, Day 28
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Rescue Analgesic Consumption
時間枠:Day 0 through Day 14
|
Total number of paracetamol and diclofenac doses consumed during the 14-day study period.
|
Day 0 through Day 14
|
|
Postoperative Complications
時間枠:Day 7, Day 14, Day 28
|
Incidence of bleeding, infection, urinary retention, and anal stenosis.
Binary (yes/no) for each.
|
Day 7, Day 14, Day 28
|
|
Return to Normal Daily Activities
時間枠:Day 28
|
Number of days until patient reports return to normal daily activities (self-reported).
|
Day 28
|
|
Return to Work
時間枠:Day 28
|
Number of days until return to employment or usual occupational duties (self-reported).
|
Day 28
|
|
Patient Satisfaction
時間枠:Day 28
|
Overall satisfaction with pain management and recovery, measured on a Likert scale or binary satisfied/dissatisfied.
|
Day 28
|
|
Adverse Events - General
時間枠:Throughout 14-day treatment and Day 28
|
Incidence of any serious or non-serious adverse event, including allergic reactions, gastrointestinal symptoms.
|
Throughout 14-day treatment and Day 28
|
|
Adverse Events - Cardiovascular
時間枠:Throughout 14-day treatment and Day 28
|
Incidence of hypotension (systolic blood pressure [SBP] < 90 mmHg), dizziness, flushing, headache, tachycardia.
|
Throughout 14-day treatment and Day 28
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:Dr. Yasser Abdurabo Obadiel, Associate Professor、Faculty of Medicine and Health Sciences, Sana'a University
出版物と役立つリンク
一般刊行物
- Jin J, Unasa H, Bahl P, Mauiliu-Wallis M, Svirskis D, Hill A. Can Targeting Sphincter Spasm Reduce Post-Haemorrhoidectomy Pain? A Systematic Review and Meta-Analysis. World J Surg. 2023 Feb;47(2):520-533. doi: 10.1007/s00268-022-06807-3. Epub 2022 Nov 10.
- Golfam F, Golfam P, Golfam B, Pahlevani P. Comparison of topical nifedipine with oral nifedipine for treatment of anal fissure: a randomized controlled trial. Iran Red Crescent Med J. 2014 Aug;16(8):e13592. doi: 10.5812/ircmj.13592. Epub 2014 Aug 5.
- Perrotti P, Dominici P, Grossi E, Cerutti R, Antropoli C. Topical nifedipine with lidocaine ointment versus active control for pain after hemorrhoidectomy: results of a multicentre, prospective, randomized, double-blind study. Can J Surg. 2010 Feb;53(1):17-24.
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- NIFEDIPINE-HD-2026-SANA
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。